26Jun 2017

CLINICAL OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH ACS TREATED WITH CONCOMITANT USE OF TICAGRELOR AND CLOPIDOGREL.

  • Chapidze Emergency Cardiology Center.
  • Institute of Clinical Cardiology.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Objectives: The purpose of our study was to compare the effects of ticagrelor versus clopidogrel on the quality of life (QOL) in patients with acute coronary syndrome (ACS) at admission and at 12 months after antiaggregant treatment. Methods: Data was collected from 104 patients hospitalized for ACS. Patients were assigned to ticagrelor (group I) or to clopidogrel (group II) therapy. In order to measure QOL a Medical Outcomes Study Short-Form (SF)-36 was used. It contained 36 questions to measure 8 domains: physical status, social functioning, role limitations due to physical and emotional problems, mental health, energy/vitality, bodily pain, general health perception and change in health over the past year. The final score was transformed to a 100-point scale, where 100 is the best possible health. Results: The number of points for each question of the physical status and mental state indicators before antiaggregant therapy ranged from 0 to 100. In ticagrelor group the total number of points averaged 25.91?14.7. In the post treatment phase positive dynamics has been observed. It significantly (p<0.004) increased and reached 77.24?8.8. In clopidogrel group the total number of points averaged 25.93?14.2, and also increased and reached 71.38?8.0 after the treatment (P<0.004). In the pain domain better results were achieved in the ticagrelor group. Statistically significant difference was recorded (P<0.001). Analysis of the mental state indicators in post-treatment phase revealed statistically significant increase in ticagrelor and clopidogrel groups. Social activity was higher in ticagrelor group. Statistically significant difference was recorded (P<0.001). The change in health status of the patients of the 1st and 2nd groups compared to the previous year improved and increased by 31% and 28% respectively. Conclusion: ticagrelor and clopidogrel treatment resulted in improvement of QOL in patients with ACS. No treatment difference in QOL between patients treated with ticagrelor and patients treated with clopidogrel was found, except pain and social activity. According to these indicators reliably better result was achieved in patients treated with ticagrelol. Prior cardiovascular events and baseline psychosocial characteristics, including depressive symptoms, were predictors of QOL for patients after ACS.

  1. Theroux P, Fuster V. Acute coronary syndromes. Unstable angina and non-Q wave myocardial infarction. Circulation 1998; 97:1195-1206
  2. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-2578
  3. Brink E, Grankvist G, Karlson BW, et al. Health-related quality of life in women and men one year after acute myocardial infarction. Qual Life Res 2005;14:749-757
  4. Hawkes AL, Patrao TA, Ware R, et al. Predictors of physical and mental health-related quality of life outcomes among myocardial infarction patients. BMC Cardiovasc Dis 2013;13:69
  5. Pavlides G, Drossinos V, Dafni C, et al. Current management and quality of life of patients with acute coronary syndrome undergoing percutaneous coronary intervention in Greece: 12-month results from antiplatelet therapy observational study II (APTOR II). Hellenic J Cardiol 2013;54:255-263
  6. Stewart AL, Hays RD, Ware JE. The MOS Short-form General Health Survey: reliability and validity in patient population. Med Care 1988;26:724-735
  7. Schweikert B, Hahmann H, Leidl R. Validation of the EuroQoLquestionnaire in cardiac rehabilitation. Heart 2006;92:62-67
  8. Hage C, Mattsson E, Stahle A. Long-term effects of exercise training on physical activity level and quality of life in elderly coronary patients ? a three- to six-year follow-up. Physiother Res Int 2003;8:13-22
  9. Kruse M, Hochstrasser S, Zwisler AD, et al. Comprehensive cardiac rehabilitation: a cost assessment based on a randomized clinical trial. Int J Technol Assess Health Care 2006;22:478-483
  10. Lacey EA, Musgrave RJ, Freeman JV, et al. Psychological morbidity aftermyocardial infarction in an area of deprivation in the UK: evaluation of a self-help package. Eur J Cardiovasc Nurs 2004;3:219-224
  11. Kim J, Henderson RA, Pocock SJ, et al. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). J Am Coll Cardiol 2005;45:221-228
  12. Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from MERLIN-TIMI 36 randomized trial. Circ Cariovasc Qual Outcomes 2008;1:107-115
  13. Azmi S, Goh A, Fong A, Anchah L. Quality of life among patients with acute coronary syndrome in Malaysia. Value in health regional issues 6C (2015), 80-83
  14. Levin L-A, Wallentin L, Bernfort L, et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes ? results from the PLATO trial. Value in Health 2013; 16:574-80
  15. Janzon M, Levin LA, Swahn E. Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial. Am Heart J 2004;148:114-21
  16. Swedeheart Arsrapport (Annual report). Uppsala, Sweden: UCR, 2010
  17. Brazier J, Fitzpatrick R. Measures of health ?related quality of life in an imperfect world: a comment on Dowie. Health Econ 2002;11(1):17-9: discussion 21-22
  18. Guyatt G. Commentary on Jack Dowie, ?Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions?. Health Econ 2002;11(1):9-12: discussion 21-22
  19. Ware J, Kosinski M, Keler S. SF-36 physical and mental health summary scales: a user?s manual. 5th Boston: Health Assessment Lab; 1994
  20. Ware JE. SF-36 physical and mental health summary scales. Ann Rev Public Health 1995;16:327-354

[L. Kopaleishvili and I. Jashi. (2017); CLINICAL OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH ACS TREATED WITH CONCOMITANT USE OF TICAGRELOR AND CLOPIDOGREL. Int. J. of Adv. Res. 5 (Jun). 1850-1857] (ISSN 2320-5407). www.journalijar.com

L. Kopaleishvil1, I. Jashi2

DOI:

Article DOI: IJAR-18294      
DOI URL: https://dx.doi.org/IJAR-18294

Download Full Paper

Download PDF No. of Downloads: 23 | No. of Views: 126